A novel HPV 16 L1-based chimeric virus-like particle containing E6 and E7 seroreactive epitopes permits highly specific detection of antibodies in patients with CIN 1 and HPV-16
Por:
Monroy-García A., Gómez-Lim M.A., Weiss-Steider B., Paz-de la Rosa, G, Hernández-Montes J., Pérez-Saldaña K., Tapia-Guerrero Y.S., Toledo-Guzmán M.E., Santiago-Osorio E., Sanchez-Peña H.I., Mora-Garcia, MD
Publicada:
9 feb 2011
Resumen:
Background: The presence of IgG antibodies to HPV-16 L1-virus like particles (VLPs) in serum has been reported as a result of persistent exposure to the virus and as a marker of disease progression. However, detection of VLP-specific antibodies in sera does not always indicate a malignant lesion as positive results may also be due to a nonmalignant viral infection. Furthermore, malignant lesions are associated with an increased antibody titer for E6 and E7 proteins. The aim of this study was to develop an ELISA using a novel chimeric virus-like particle (cVLP) encoding an L1 protein fused with a string of HPV-16 E6 and E7 seroreactive epitopes to its C-terminus to be used for detection of HPV-16 specific antibodies in patients with cervical intraepithelial lesion grade 1 (CIN 1). Results: The sera of 30 patients with CIN 1 who also tested positive for HPV-16 DNA and of 30 age-matched normal donors negative for HPV infection were tested for the presence of IgG antibodies specific for ei
Filiaciones:
Monroy-García A.:
Univ Nacl Autonoma Mexico, Lab Inmunobiol, Unidad Invest Diferenciac Celular & Canc, FES Zaragoza, Mexico City, DF, Mexico
Univ Nacl Autonoma Mexico, Fac Estudios Super Zaragoza, UMIEZ, Lab 3,PB, Mexico City 09230, DF, Mexico
Gómez-Lim M.A.:
Centro de Investigación y de Estudios Avanzados (CINVESTAV), Unidad Irapuato, Guanajuato, Mexico
Weiss-Steider B.:
Univ Nacl Autonoma Mexico, Lab Inmunobiol, Unidad Invest Diferenciac Celular & Canc, FES Zaragoza, Mexico City, DF, Mexico
Univ Nacl Autonoma Mexico, Fac Estudios Super Zaragoza, UMIEZ, Lab 3,PB, Mexico City 09230, DF, Mexico
Hernández-Montes J.:
Univ Nacl Autonoma Mexico, Lab Inmunobiol, Unidad Invest Diferenciac Celular & Canc, FES Zaragoza, Mexico City, DF, Mexico
Univ Nacl Autonoma Mexico, Fac Estudios Super Zaragoza, UMIEZ, Lab 3,PB, Mexico City 09230, DF, Mexico
Pérez-Saldaña K.:
Unidad de Investigación Médica en Enfermedades Oncológicas, IMSS, CMN SXXI, Mexico
Tapia-Guerrero Y.S.:
Univ Nacl Autonoma Mexico, Lab Inmunobiol, Unidad Invest Diferenciac Celular & Canc, FES Zaragoza, Mexico City, DF, Mexico
Univ Nacl Autonoma Mexico, Fac Estudios Super Zaragoza, UMIEZ, Lab 3,PB, Mexico City 09230, DF, Mexico
Toledo-Guzmán M.E.:
Univ Nacl Autonoma Mexico, Lab Inmunobiol, Unidad Invest Diferenciac Celular & Canc, FES Zaragoza, Mexico City, DF, Mexico
Univ Nacl Autonoma Mexico, Fac Estudios Super Zaragoza, UMIEZ, Lab 3,PB, Mexico City 09230, DF, Mexico
Santiago-Osorio E.:
Univ Nacl Autonoma Mexico, Lab Hematopoyesis, Unidad Invest Diferenciac Celular & Canc, FES Zaragoza, Mexico City, DF, Mexico
Sanchez-Peña H.I.:
Departamento de Ginecología, H.G.Z No. 2-A, Troncoso, Mexico
Mora-Garcia, MD:
Univ Nacl Autonoma Mexico, Lab Inmunobiol, Unidad Invest Diferenciac Celular & Canc, FES Zaragoza, Mexico City, DF, Mexico
Univ Nacl Autonoma Mexico, Fac Estudios Super Zaragoza, UMIEZ, Lab 3,PB, Mexico City 09230, DF, Mexico
All Open Access, Gold
|